| ￥4500 | |
| Z05627-100 | |
|
|
|
|
|
|
|
|
|
| Species | Human | ||||
| Protein Construction |
|
||||
| Purity | > 95% as determined by BisTris PAGE | ||||
| Endotoxin Level | Less than 1 EU per μg by the LAL method. | ||||
| Biological Activity | Measured by its binding ability in a functional ELISA. Test result was comparable to standard batch. | ||||
| Expression System | E.coli | ||||
| Theoretical Molecular Weight | 46.9 kDa | ||||
| Apparent Molecular Weight | Due to autocatalytic cleavage, the protein migrates to 18 kDa&25-30 kDa based on Bis-Tris PAGE result. | ||||
| Formulation | Lyophilized from 0.22 μm filtered solution in 20 mM Tris, 200 mM NaCl (pH 9.0). | ||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||
| Storage & Stability | Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles. |
| Target Background | The pathogenesis of severe acute respiratory disease syndrome (SARS) is not fully understood. One case-control study has reported an association between susceptibility to SARS and mannan-binding lectin (MBL) in China. As the downstream protein of MBL, variants of the MBL-associated serine protease-2 (MASP2) gene may be associated with SARS coronavirus (SARS-CoV) infection in the same population. |
| Synonyms | MAP19; MASP-2; MASP1P1; sMap |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
